Adverse drug reaction of the month

Severe cholestatic hepatitis following cloxacillin treatment

Sorel Goland, Stephen DH Malnick, Raia Gratz, Edith Feldberg, David Geltner, Zev M Sthoeager

Summary
We describe a 77-year-old woman who developed fatigue, fever, a maculopapular rash and severe cholestatic hepatitis two weeks after receiving cloxacillin and ofloxacin.

Keywords: hepatitis; cloxacillin; ofloxacin

Semisynthetic penicillins are widely used antibiotics. Hepatotoxicity (mainly cholestatic) associated with these drugs is a rare, but well described phenomenon.1,2 Several series of cholestatic hepatitis have been reported after treatment with flucloxacillin,2,4 whereas only isolated cases related to cloxacillin have been described.5-10 Cholestatic jaundice may develop up to seven weeks following cessation of treatment.1 It may present as a mild disorder or as severe, prolonged cholestatic hepatitis which may lead to a fatal outcome despite cessation of the drug.2 2 The optimal treatment (in addition to discontinuation of the drug) is unclear. We describe a patient who developed a severe and prolonged cholestatic hepatitis which we believe was related to cloxacillin treatment.

Case report
A previously healthy 77-year-old woman underwent an elective repair of her left hallux valgus under local anaesthesia. She subsequently developed an operative wound infection and was treated intravenously for a total of 14 days with cloxacillin 6 g/day and ofloxacin 400 mg/day. Two weeks after cessation of the treatment she complained of increasing weakness and a pruritic maculopapular rash. Physical examination was unremarkable except for a widespread maculopapular rash with signs of scratching. There was neither abdominal tenderness nor hepatosplenomegaly. Laboratory tests revealed a haemoglobin of 11.6 g/dl, white blood cells 4.7×10⁹/l, with 9.5% eosinophils (total eosinophils 423/ml), and platelets 273×10⁹/l. Prothrombin time was normal. The erythrocyte sedimentation rate was 66 mm/h. Serum glucose, electrolytes and renal function tests were all normal. Total serum bilirubin was 221 µmol/l (direct 144 µmol/l). There was an increase of serum transaminases: alanine transaminase 144 IU/l (normal <41) and aspartate transaminase 313 IU/l (normal <37). The alkaline phosphatase was 394 IU/l (normal 53–128) with γ-glutamyl transferase of 212 IU/l (normal 11–49). Serum cholesterol was 381 mg/dl. Repeated serological tests for hepatitis A, B and C, CMV, EBV and Q fever, as well as antinuclear, antimitochondrial and antismooth muscle auto-antibodies, were all negative. IgE level was 354 IU/ml (normal 90–110).

Abdominal ultrasound and computed tomography (CT) were both normal except for the presence of several small gallstones with no signs of inflammation or bile duct obstruction. The jaundice deepened reaching a bilirubin of 391 µmol/l (mostly direct). Liver biopsy showed a portal tract infiltrate of lymphocytes and eosinophils, prominent cholestasis in the hepatocytes and focal hepatocellular necrosis, compatible with an exudative type of drug-induced cholestasis. Peripheral blood lymphocyte proliferation tests with both ofloxacin and cloxacillin were negative.

After one month of jaundice the patient's general condition declined and it was decided to give 40 mg prednisone treatment with a presumptive diagnosis of drug-induced cholestasis. Within 10 days there was a dramatic response in her general condition and a decrease in the bilirubin and transaminases which later returned to normal. She subsequently received ofloxacin for a urinary tract infection from her family physician and no ill-effects were noted. The patient remains well with no signs of any liver damage, at two years of follow-up.

Discussion
We describe a patient who developed a prolonged, severe cholestatic jaundice 14 days after completing treatment with cloxacillin and ofloxacin for a wound infection. The jaundice was associated with allergic features such as rash and eosinophilia and responded dramatically to steroid treatment. Penicillinase-resistant penicillins are widely used drugs. Hepatotoxicity associated with their usage is not a common complication. Most reports involve series of cases following treatment with flucloxacillin,1 2 5 with an incidence in Australia of between 1:12 000 and 1:100 000 and in Sweden of between 1:11 000 and 1:30 000.7 5 Flucloxacillin-related hepatotoxicity is predominantly of a cholestatic type,1 5 found mainly in females, with a mean age of 58 years. The mean period of time from initiation of treatment to disease was 22.6 days.7 There are only a few...
cases of cholestatic hepatitis associated with cloxacillin, as in our patient.  

In addition to cloxacillin, our patient was treated with ofloxacin. Ofloxacin is an antibiotic of the quinolone group and reports of hepatotoxicity associated with its use are extremely rare.  

All the cases demonstrated only mild acute hepatitis without features of cholestasis, which was dominant in our case. Our patient received an inadvertent rechallenge with ofloxacin with no cholestasis or liver enzyme abnormality. Thus, we believe that the cholestatic hepatitis observed in our patient was related to cloxacillin rather than to ofloxacin.

The usual histological features of drug-induced cholestasis are divided into two types: canalicular ('bland') and exudative. The former type is pathologically 'bland' due to changes in the membrane of the liver cells. The exudative type, is predominantly cholestatic with some features of hepatocellular necrosis and inflammation (cholangitis) and is clinically hypersensitivity-mediated, usually associated with rash, fever and eosinophilia, as in our patient.

The mechanism of the reaction to the cloxacillin is unclear. The nature of the liver biopsy, the clinical presentation with rash and eosinophilia, and the dramatic response to the steroid treatment suggest a hypersensitivity allergic mechanism, which is not dose-dependent. The patient received a daily dose of 6 g of cloxacillin which is the maximum recommended dose in the British National Formulary for severe infections. In addition, the bioavailability of cloxacillin is lower than that of flucloxacillin. A previous report of cloxacillin-associated hepatitis demonstrated a positive macrophage inhibition test, although in our patient there was no peripheral blood mononuclear cell response to cloxacillin. We believe that it is more likely that the severe jaundice seen in our patient was an idiosyncratic hypersensitivity reaction and not a direct dose-dependent reaction.

There are scarce data regarding treatment. The majority of cases resolve spontaneously, although fatal cases have been reported. Although our patient responded dramatically to steroids, the role of steroid treatment is uncertain. We suggest that corticosteroid treatment should be considered in patients with severe, prolonged, drug-induced cholestatic hepatitis with features of hypersensitivity.

---

**Learning points**

- cloxacillin can cause a severe cholestatic jaundice
- the jaundice may appear several weeks after stopping taking the medication
- steroid therapy can produce a dramatic response

---

Severe cholestatic hepatitis following cloxacillin treatment

Sorel Goland, Stephen DH Malnick, Raia Gratz, Edith Feldberg, David Geltner and Zev M Sthoeeger

doi: 10.1136/pgmj.74.867.59

Updated information and services can be found at:
http://pmj.bmj.com/content/74/867/59

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/